CLSD
Clearside Biomedical, Inc.
Set alert
Day range unavailable
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- —
- Prev close
- 0.41
- Mkt cap
- 66.72M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.76
- Beta
- 2.33
- Short ratio
- 1.21
- Inst. own
- 23.17%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.07
- 200-d avg
- 1.22
- 1y target
- 6.00
News
3 months ago businesswire.com
Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
NEW YORK--(BUSINESS WIRE)--Clearside Biomedical, Inc. (“Clearside” or the “Company”) today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to…
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
11 months ago benzinga.com
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 months ago globenewswire.com
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations…
11 months ago benzinga.com
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
11 months ago zacks.com
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $1.5 per share a year ago.
1 year ago defenseworld.net
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Hold” from Brokerages
Clearside Biomedical, Inc. (NASDAQ: CLSD - Get Free Report) has earned a consensus recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports.…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
1 year ago globenewswire.com
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago zacks.com
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago globenewswire.com
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
1 year ago globenewswire.com
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
1 year ago globenewswire.com
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
1 year ago zacks.com
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
1 year ago globenewswire.com
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the…
1 year ago zacks.com
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
1 year ago globenewswire.com
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month…
1 year ago globenewswire.com
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the…
1 year ago globenewswire.com
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to…
1 year ago zacks.com
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 year ago globenewswire.com
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago globenewswire.com
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the…
1 year ago seekingalpha.com
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer…
1 year ago zacks.com
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.08 per share a year ago.
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
-
2 years ago benzinga.com
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 225 companies set new 52-week lows.